Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models

被引:211
作者
Flies, Dallas B. [1 ]
Wang, Shengdian [2 ]
Xu, Haiying [3 ]
Chen, Lieping [1 ,4 ]
机构
[1] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06519 USA
[2] Chinese Acad Sci, Inst Biophys, Ctr Infect & Immun, Beijing 100190, Peoples R China
[3] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[4] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06519 USA
基金
美国国家卫生研究院;
关键词
CELL-ACTIVATION; LYMPHOCYTE; ANTIGEN; PATHWAY; PD-1;
D O I
10.4049/jimmunol.1100660
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Upon interaction with B7 homolog 1, programmed death-1 (PD-1) transmits a critical coinhibitory signal to T cells to negatively regulate immune responses. By extensively searching the genomic database with the IgV region of PD-1, we identified a homolog and named it PD-1 homolog (PD-1H). PD-1H is broadly expressed on the cell surface of hematopoietic cells and could be further upregulated on CD4(+) and CD8(+) T cells following activation. We have generated an mAb against PD-1H, which strikingly prevents acute graft-versus-host disease in semi-and fully allogeneic murine models, leading to full chimerism following treatment. Graft-versus-host disease remains a primary hindrance to successful allogeneic hematopoietic cell transplantation therapy for the treatment of hematologic malignancy. Therefore, manipulation of PD-1H function may provide a new modality for controlling T cell responses to allogeneic tissues in transplant medicine. The Journal of Immunology, 2011, 187: 1537-1541.
引用
收藏
页码:1537 / 1541
页数:5
相关论文
共 17 条
[1]   The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation [J].
Cai, Guifang ;
Freeman, Gordon J. .
IMMUNOLOGICAL REVIEWS, 2009, 229 :244-258
[2]   The B7 family revisited [J].
Greenwald, RJ ;
Freeman, GJ ;
Sharpe, AH .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :515-548
[3]   PD-1 and its ligands in tolerance and immunity [J].
Keir, Mary E. ;
Butte, Manish J. ;
Freeman, Gordon J. ;
Sharpel, Arlene H. .
ANNUAL REVIEW OF IMMUNOLOGY, 2008, 26 :677-704
[4]   Emerging drugs for acute graft-versus-host disease [J].
Khaled, Yasser ;
Reddy, Pavan ;
Krijanovski, Oleg .
EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (02) :219-232
[5]   Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation [J].
Kuipers, Harmjan ;
Muskens, Femke ;
Willart, Monique ;
Hijdra, Danielle ;
van Assema, Friso B. J. ;
Coyle, Anthony J. ;
Hoogsteden, Henk C. ;
Lambrecht, Bart N. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (09) :2472-2482
[6]   T-CELL ANTIGEN CD28 MEDIATES ADHESION WITH B-CELLS BY INTERACTING WITH ACTIVATION ANTIGEN B7/BB-1 [J].
LINSLEY, PS ;
CLARK, EA ;
LEDBETTER, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (13) :5031-5035
[7]   CTLA-4 IS A 2ND RECEPTOR FOR THE B-CELL ACTIVATION ANTIGEN-B7 [J].
LINSLEY, PS ;
BRADY, W ;
URNES, M ;
GROSMAIRE, LS ;
DAMLE, NK ;
LEDBETTER, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (03) :561-569
[8]   Mechanisms maintaining peripheral tolerance [J].
Mueller, Daniel L. .
NATURE IMMUNOLOGY, 2010, 11 (01) :21-27
[9]   Inducible costimulator costimulates cytotoxic activity and IFN-γ production in activated murine NK cells [J].
Ogasawara, K ;
Yoshinaga, SK ;
Lanier, LL .
JOURNAL OF IMMUNOLOGY, 2002, 169 (07) :3676-3685
[10]   Acute graft-versus-host disease: new treatment strategies [J].
Paczesny, Sophie ;
Choi, Sung W. ;
Ferrara, James L. M. .
CURRENT OPINION IN HEMATOLOGY, 2009, 16 (06) :427-436